We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 43

Time for change? Potential impact of Canada’s trade negotiations on pharma patents

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Bringing a new drug to market is a costly and time-consuming endeavour. It is a process inherent with the risk of failure. In recognition of this

Methods of medical treatment claims issues in Canada, US and Europe

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, European Union, USA
  • -
  • November 30 2012

In this presentation, Scott Foster and Konrad Sechley address methods of medical treatment claims issues in Canada, US and Europe

Impacts of the Amazon.com decisions on medical use claims in Canada

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • July 13 2012

Methods of medical treatment and surgery are not statutory subject matter in Canada

Apotex loses the war in Canada and the battle in England: UK courts rely on Canadian decision to find Apotex acting unlawfully in cCnada has consequences in eErope

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, United Kingdom
  • -
  • October 13 2011

Servier developed perindopril erbumine (“perindopril”) which is a successful long lasting ACE inhibitor sold under the trade-mark COVERSYL

Novopharm v Pfizer, motion for interim relief pending appeal, pregabalin, October 5, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 24 2010

See the earlier decisions in this case in the May 2010 and July 2010 editions of this newsletter

Merck v Apotex, PMNOC proceedings, dorzolamide and timolol, October 22, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 24 2010

Merck’s patent in this case (the ‘965 patent) covered the co-administration and co-formulation of dorzolamide and timolol (which was sold as COSOPT

Merck v Apotex, PMNOC proceedings, dorzolamide, October 22, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 24 2010

This proceeding for an order of prohibition was a companion case to the case described below

Hospira v Eli Lilly, appeal of order for further and better production of documents, gemcitabine, October 26, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 24 2010

Eli Lilly alleged that gemcitabine made in China and imported into Canada by Hospira infringes Eli Lilly's patent for an intermediate process step in the manufacture of gemcitabine

Eli Lilly v Apotex, PMNOC proceedings, strattera, October 29, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 24 2010

Eli Lilly sought an order of prohibition against Apotex until expiry of its patent for atomoxetine (the '735 patent

Janssen v Mylan, unsuccessful PMNOC proceedings, galantamine, November 11, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 24 2010

Janssen sought an order of prohibition until expiry of its '950 patent which claimed the use of an optimum dosing regimen of galantamine to treat Alzheimer's Disease